|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD
96.33 billion
|
|
CAGR
(2023-2028)
|
7.55%
|
|
Fastest
Growing Segment
|
Monoclonal Antibodies
|
|
Largest
Market
|
North
America
|
Market Overview
Global Cancer Biological Therapy Market has valued
at USD 96.33 billion in 2022 and is anticipated to project impressive growth in
the forecast period with a CAGR of 7.55% through 2028. The global cancer
biological therapy market refers to the rapidly evolving field of cancer
treatment that utilizes biological agents, such as monoclonal antibodies,
cytokines, and vaccines, to target and combat cancer cells. This market has
witnessed significant growth and innovation over the years due to advances in
biotechnology and a growing understanding of the molecular mechanisms underlying
cancer.
Key Market Drivers
Rising Cancer Incidence
Cancer has long been one of humanity's most
formidable adversaries, affecting millions of lives across the globe. Recent
years have witnessed a troubling surge in cancer incidence rates, with the
disease becoming an ever-increasing public health concern. Paradoxically, this
ominous trend has also created an environment ripe for innovation and
advancement in the field of cancer treatment, particularly in the realm of
cancer biological therapies.
According to data from the World Health
Organization (WHO), the incidence of cancer has been steadily climbing, with
millions of new cases diagnosed each year. This upward trajectory is driven by
a combination of factors, including an aging population, lifestyle changes,
environmental factors, and improved cancer detection methods.
The escalating cancer burden has created a pressing
need for more effective and targeted treatments. Conventional treatments like
chemotherapy and radiation therapy, while valuable, often come with severe side
effects and limited efficacy. Biological therapies, on the other hand, offer
the promise of better outcomes with fewer side effects. The genetic diversity
of cancer is well-documented, and this diversity often necessitates
personalized treatment approaches. Biological therapies, such as targeted therapies,
are designed to pinpoint specific molecular abnormalities or mutations in
cancer cells. This precision allows for the development of tailored treatment
plans, increasing their effectiveness. Immunotherapy, a subset of biological
therapy, has made remarkable strides in recent years. These treatments harness
the body's immune system to identify and attack cancer cells, offering the
potential for long-lasting remissions and even cures. The increasing prevalence
of immunotherapies like checkpoint inhibitors and CAR-T cell therapy is
directly tied to their success in treating various cancer types. The
pharmaceutical industry has responded to the rising cancer incidence by investing
heavily in research and development. As the demand for more effective
treatments grows, pharmaceutical companies are racing to develop and bring to
market innovative cancer biological therapies, creating a competitive and
dynamic landscape. Genetic testing and molecular profiling have become integral
to cancer diagnosis and treatment planning. As the understanding of cancer
genetics deepens, personalized medicine approaches are being employed to tailor
cancer biological therapies to individual patients, optimizing treatment
outcomes. The surge in cancer cases has prompted an increase in clinical trials
for novel biological therapies. Regulatory agencies have also streamlined
approval processes to expedite promising treatments to patients, further
facilitating market growth. The global cancer biological therapy market is
expanding beyond traditional markets, with emerging economies in Asia, Latin
America, and the Middle East witnessing rapid growth. Improved healthcare
infrastructure and increasing awareness of advanced cancer treatments are
contributing to this expansion.
Advancements in Biotechnology
Biotechnology has emerged as a game-changer in the
field of cancer treatment, revolutionizing the way we combat this complex and
devastating disease. Advancements in biotechnology have led to the development
of innovative and highly targeted cancer biological therapies that offer new
hope for patients worldwide.
Biotechnology encompasses a broad spectrum of
techniques and technologies that leverage biological systems, living organisms,
or their derivatives to develop new products and processes. In the context of
cancer treatment, biotechnology has become instrumental in understanding the
underlying mechanisms of the disease, discovering novel therapeutic targets,
and designing precision treatments.
Advances in biotechnology have deepened our
understanding of the molecular and genetic basis of cancer. Researchers can now
identify specific genetic mutations, biomarkers, and signaling pathways that
drive tumor growth. This knowledge has paved the way for the development of
targeted therapies, a cornerstone of cancer biological treatments.
Biotechnology has facilitated the production of
monoclonal antibodies, which are engineered to bind to specific antigens on
cancer cells. These antibodies can either block the growth signals of cancer
cells or trigger the immune system to attack them. Monoclonal antibodies like
trastuzumab (Herceptin) and rituximab (Rituxan) have revolutionized cancer
treatment, particularly in breast and blood cancers.
Biotechnological advancements have enabled the
development of cancer vaccines designed to stimulate the patient's immune
system to recognize and attack cancer cells. Vaccines such as Provenge
(sipuleucel-T) for prostate cancer and various therapeutic cancer vaccine
candidates have shown promise in clinical trials.
Gene therapy, a cutting-edge biotechnological
approach, involves modifying a patient's own genes to treat or prevent disease.
In the context of cancer biological therapy, gene therapies are being developed
to target and correct genetic mutations responsible for cancer. CAR-T cell
therapies, which genetically engineer a patient's immune cells to fight cancer,
exemplify this innovation.
Biotechnology has transformed drug discovery
processes. High-throughput screening, computational biology, and bioinformatics
tools enable researchers to identify potential drug candidates more
efficiently. This has led to the discovery of novel molecules for cancer
treatment.
Biotechnology has facilitated the discovery and
validation of biomarkers, which are crucial for patient stratification and
treatment response prediction. Biomarker-driven approaches help identify
patients who are most likely to benefit from specific cancer biological
therapies, making treatments more effective and personalized.
Biotechnology has improved bioprocessing and
manufacturing techniques, ensuring the scalable production of biological
therapies. This has lowered production costs and increased the availability of
these treatments.
Immunotherapy Revolution
Immunotherapy, a groundbreaking approach to cancer
treatment, has ignited a revolution in the field of oncology. This remarkable
advancement harnesses the body's immune system to fight cancer cells, providing
hope to patients and transforming the landscape of cancer care.
Immunotherapy represents a paradigm shift in cancer
treatment. Unlike traditional therapies like chemotherapy and radiation, which
directly target cancer cells, immunotherapy focuses on strengthening the body's
own defenses against cancer. It stimulates the immune system to recognize and
destroy cancer cells, offering several advantages.
Immunotherapy is highly precise. It targets only
cancer cells while sparing healthy tissues, minimizing side effects. Some
immunotherapies can induce durable responses, with the potential for sustained
remission or even cures. Immunotherapy has expanded the arsenal of treatment
options, particularly for advanced and hard-to-treat cancers.
Immunotherapy has demonstrated efficacy in various
cancer types, including melanoma, lung, bladder, and kidney cancers, among
others. As research continues, the potential applications of immunotherapy are
expected to grow, widening its reach in the market. Checkpoint inhibitors are a
class of immunotherapies that block proteins that inhibit the immune response,
allowing the immune system to recognize and attack cancer cells. Drugs like
pembrolizumab (Keytruda) and nivolumab (Opdivo) have achieved remarkable
success in clinical trials and have been approved for multiple indications,
fueling market growth. CAR-T cell therapy is a type of immunotherapy that
involves modifying a patient's T cells to express chimeric antigen receptors
(CARs), which can recognize and target cancer cells. CAR-T therapies have shown
exceptional results in treating certain blood cancers, such as leukemia and
lymphoma. Researchers are exploring the potential of combining immunotherapies
with other treatments, such as chemotherapy and targeted therapies. These
combination approaches aim to enhance the effectiveness of cancer treatment and
broaden the scope of immunotherapy applications. The ongoing research and
development of immunotherapies through clinical trials are expanding the
portfolio of available treatments. New immunotherapeutic agents and novel
combinations are continuously being tested, driving innovation and market
growth.
Targeted Therapies
Targeted therapies represent a transformative
approach to cancer treatment, offering new hope to patients by directly
targeting the molecular and genetic abnormalities that drive cancer growth. In
recent years, these precise and innovative treatments have played a pivotal
role in shaping the landscape of the global cancer biological therapy market.
Targeted therapies minimize harm to healthy
tissues, reducing the often-debilitating side effects associated with
traditional treatments. By directly addressing the underlying genetic or
molecular drivers of cancer, targeted therapies can be more effective,
especially in cancers where traditional treatments have limited impact. Targeted
therapies are often tailored to individual patients based on genetic or
molecular profiling, allowing for personalized treatment plans.
Advances in genomics and molecular biology have led
to the discovery of numerous biomarkers and genetic mutations that drive
cancer. Targeted therapies are developed to specifically address these
aberrations, enabling more precise treatments. The pharmaceutical industry has
invested heavily in research and development, leading to the creation of a wide
range of targeted therapies. Drugs like imatinib (Gleevec), which targets the
BCR-ABL gene in chronic myeloid leukemia (CML), have achieved remarkable success.
Targeted therapies have demonstrated efficacy in various cancer types,
including breast, lung, colorectal, and melanoma. As researchers uncover new
targetable mutations, the scope of targeted therapy applications is expected to
grow. Researchers are exploring the potential of combining targeted therapies
with other treatments, such as immunotherapies and traditional chemotherapy.
These combinations aim to enhance treatment effectiveness and broaden the range
of treatable cancers. Ongoing clinical trials continue to expand the portfolio
of available targeted therapies. New agents and innovative combinations are
constantly being tested, driving innovation and market growth.
Download Free Sample Report
Key Market Challenges
High Costs and Accessibility
One of the most pressing challenges is the high
cost associated with many cancers’ biological therapies. These treatments can
be expensive to develop, produce, and administer. Accessibility to these
therapies becomes a critical issue, as not all patients can afford them,
leading to disparities in care. Ensuring equitable access to these life-saving
treatments remains a global challenge.
Resistance to Treatment
Over time, some cancer cells can develop resistance
to targeted therapies, rendering them less effective. This phenomenon, known as
treatment resistance, can limit the long-term success of these therapies.
Researchers are actively working to understand and address resistance
mechanisms, but it remains a significant challenge in the field.
Side Effects and Toxicities
While targeted therapies are often less toxic than
traditional treatments like chemotherapy, they are not without side effects.
Patients may experience adverse events, including skin reactions,
gastrointestinal problems, and immune-related complications. Managing these
side effects while maintaining treatment efficacy is a delicate balance.
Key Market Trends
Immunotherapy Combinations
Immunotherapy has revolutionized cancer treatment,
and the trend toward combining different immunotherapies or immunotherapy with
other treatment modalities is expected to gain traction. Researchers are
exploring the synergy between checkpoint inhibitors, CAR-T cell therapy, and
cancer vaccines to enhance the effectiveness of immune-based therapies.
Biomarker-Driven Therapies
Precision medicine is increasingly guiding
treatment decisions in oncology. The identification of novel biomarkers,
including genetic mutations and molecular signatures, will continue to drive
the development of highly targeted therapies. Biomarker-driven approaches
ensure that patients receive the most appropriate treatment based on their
unique tumor characteristics.
CAR-T Cell Therapy Expansion
CAR-T cell therapy, a form of immunotherapy that
modifies a patient's T cells to target cancer cells, is gaining momentum. As
research progresses, we can anticipate the approval of CAR-T therapies for
additional cancer types beyond blood cancers, further broadening their
applications.
Segmental Insights
Product Insights
Based on the category of Product, it is anticipated
that the antibodies sector will assume a leading position in 2022. Antibodies
are poised for substantial growth in the foreseeable future, primarily owing to
their capacity to precisely target proteins on the cell surface. This precision
makes them increasingly valuable in cancer therapy. Furthermore, the growing
preference among patients for advanced biological therapies for cancer, which
aim to mitigate the risks associated with traditional anti-cancer drug
treatments, will fuel the expansion of this segment.
These laboratory-produced antibodies are designed
to combat protein molecules expressed by malignant tumors. Examples of antibody
medications in this category include rituximab, employed in the treatment of
non-lymphoma; Hodgkin's alemtuzumab (Campath), utilized in the management of
chronic leukemia (CLL); and ipilimumab (Yervoy), employed in the treatment of
malignant melanoma. Moreover, the growing inclination towards advanced
biological treatments for cancer, as a means to reduce the risks tied to conventional
anti-cancer drugs, is poised to bring about significant growth within this
segment. For instance, in the case of breast cancer, trastuzumab (Herceptin,
Kanjinti, Ogivri) serves as an exemplar of a laboratory-developed antibody. It
operates by impeding the proliferation of cancer cells through targeted
adherence to specific regions on these cells.
Distribution Channel Insights
Retail and mail-order pharmacies are expected to
command a substantial market share in the Global Cancer Biological Therapy
Market during the forecast period for several compelling reasons. Firstly, the
increasing prevalence of cancer worldwide necessitates easy access to advanced
therapies, and retail and mail-order pharmacies provide a convenient
distribution channel for these treatments. Moreover, as patients and healthcare
providers increasingly opt for personalized cancer therapies, the ability of retail
and mail-order pharmacies to offer a wide range of biological therapies
tailored to individual patient needs positions them favorably in the market.
Additionally, the global trend toward home-based healthcare services further
accentuates the significance of these pharmacies, as they enable patients to
access and receive cancer biological therapies in the comfort of their homes,
promoting greater patient compliance and treatment effectiveness. As a result,
the retail and mail-order pharmacy segment is poised to play a pivotal role in
the growth and accessibility of cancer biological therapies during the forecast
period.
Download Free Sample Report
Regional Insights
In the cancer biological therapy market from 2023
to 2032, North America takes the lead as the prominent region. The United
States, in particular, emerges as the frontrunner both within North America and
globally, attributed to a favorable reimbursement landscape coupled with
substantial healthcare spending. Furthermore, the U.S. market benefits from an
extensive network of cancer biological vaccine and drug manufacturers,
bolstered by increased investments in research and development and government
initiatives. Accessible health insurance policies covering life-threatening
conditions incentivize individuals to seek these therapies, thereby driving
market growth. The U.S. cancer gene therapy market has also witnessed
significant expansion, thanks to a robust treatment pipeline and the increasing
focus of industry players on pioneering cancer gene therapies and their
delivery systems. An illustrative example of this trend is the extended
collaboration agreement between the Cancer Institute, Inc. and McKesson
Corporation announced on June 27, 2022.
In the second position for market profitability is
Europe, owing to its high disposable income levels and widespread awareness.
The region's substantial cancer burden, a significant elderly patient
population, and advancements in cancer therapies further contribute to the
potential for market growth in the upcoming years. Additionally, the
introduction of novel molecular techniques, an evolving healthcare sector, and
innovative technological approaches are expected to further augment the
European market's prospects.
Recent Developments
- In May 2022, the United Kingdom secured an $11.4
million grant to sustain its ongoing cancer research efforts.
- In May 2022, Enhertu received approval in the
United States for use in patients with HER2-positive metastatic breast cancer
who have previously undergone treatment with an anti-HER2-based regimen.
- In May 2021, the FDA granted approval to LUMAKRASTM
(Sotorasib), the inaugural and exclusive targeted therapy designed for the
treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell
lung cancer.
Key Market Players
- F Hoffmann-La Roche AG
- Novartis
AG
- Merck
& Co., Inc.
- Amgen Inc
- GSK PLC
- Celgene
Corp
- Pfizer
Inc
- Zydus
Lifesciences Ltd
- Sun
Pharmaceutical Industries Ltd
- Bayer AG
|
By Product
|
By Distribution Channel
|
By Region
|
- Cancer Growth Blockers
- Monoclonal Antibodies
- Vaccines
|
- Hospitals
- Retail & Mail Order Pharmacies
|
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Cancer Biological
Therapy Market has been segmented into the following categories, in addition to
the industry trends which have also been detailed below:
- Cancer Biological Therapy Market, By Product:
o Cancer Growth Blockers
o Monoclonal Antibodies
o Vaccines
- Cancer Biological Therapy Market, By Distribution Channel:
o Hospitals
o Retail & Mail Order
Pharmacies
- Cancer Biological Therapy Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Cancer
Biological Therapy Market.
Available Customizations:
Global Cancer Biological Therapy market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Cancer
Biological Therapy Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]